MNBA (4-methyl-3-nitro-benzoic acid)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 401555

CAS#: NONE

Description: MNBA, also known as 4-methyl-3-nitro-benzoic acid, is a potential cell migration inhibitor, with potential anticancer activity. T reatment with MNBA on breast cancer cells can inhibit EGF-induced migration and chemotaxis in vitro. In vivo assay demonstrated that MNBA and Paclitaxel synergistically inhibited tumor growth and metastasis in breast cancer SCID mice xenografts. These results suggest that MNBA is a potent inhibitor cancer cell chemotaxis and may be developed into a novel anti-metastasis drug . (source: Cancer Lett. 2011 Jun 1;305(1):69-75. doi: 10.1016/j.canlet.2011.02.028. Epub 2011 Mar 22.).


Chemical Structure

img
MNBA (4-methyl-3-nitro-benzoic acid)
CAS# NONE

Theoretical Analysis

MedKoo Cat#: 401555
Name: MNBA (4-methyl-3-nitro-benzoic acid)
CAS#: NONE
Chemical Formula: C8H7NO4
Exact Mass: 181.03751
Molecular Weight: 181.14548
Elemental Analysis: C, 53.04; H, 3.89; N, 7.73; O, 35.33

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-02-27. Prices are subject to change without notice.

MNBA (4-methyl-3-nitro-benzoic acid) is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Synonym: MNBA; 4methyl3nitrobenzoic acid

IUPAC/Chemical Name: 4-methyl-3-nitro-benzoic acid

InChi Key: BBEWSMNRCUXQRF-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H7NO4/c1-5-2-3-6(8(10)11)4-7(5)9(12)13/h2-4H,1H3,(H,10,11)

SMILES Code: O=C(O)C1=CC=C(C)C([N+]([O-])=O)=C1

Appearance:
Solid powder

Purity:
>98%

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 181.14548 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Chen P, Zhang X, Guo H, Ma N, Li M, Liu Z, Zhang N, Hao X. Effect of 4-methyl-3-nitrobenzoic acid on non‑small cell lung cancer cell migration. Mol Med Report. 2011 Sep-Oct;4(5):947-53. doi: 10.3892/mmr.2011.527. Epub 2011 Jul 1. PubMed PMID: 21725598.

2: Guo H, Li M, Chen P, Blake DJ, Kong X, Hao X, Niu R, Zhang N. 4-Methyl-3-nitro-benzoic acid, a migration inhibitor, prevents breast cancer metastasis in SCID mice. Cancer Lett. 2011 Jun 1;305(1):69-75. doi: 10.1016/j.canlet.2011.02.028. Epub 2011 Mar 22. Erratum in: Cancer Lett. 2012 Nov 28;324(2):232. PubMed PMID: 21429660.



Additional Information